AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.75 |
Market Cap | 7.64M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -127.9 |
PE Ratio (ttm) | -0.02 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.85 |
Volume | 74,118 |
Avg. Volume (20D) | 706,270 |
Open | 2.90 |
Previous Close | 2.89 |
Day's Range | 2.76 - 2.93 |
52-Week Range | 2.11 - 572.00 |
Beta | undefined |
About SBFM
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast c...
Analyst Forecast
According to 1 analyst ratings, the average rating for SBFM stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 431.91% from the latest price.
Next Earnings Release
Analysts project revenue of $15.50M, reflecting a 101.82% YoY growth and earnings per share of 26.8, making a -122.33% decrease YoY.
2 years ago · investorplace.com
Multiple Promising Treatments Accentuate the Bull Case for Sunshine BiopharmaSBFM stock is trading at a surprisingly low price, considering Sunshine Biopharma's demonstrably positive clinical results. The post Multiple Promising Treatments Accentuate the Bull Case for Sunshine...
2 years ago · investorplace.com
Sunshine Biopharma Stock Triples on Positive mRNA Cancer Treatment ResultsMontreal-based Sunshine Biopharma stock tripled to $6.53 on Tuesday after revealing that two of its newly designed mRNA molecules are effective in destroying cancer cells. The post Sunshine Biopharma ...